Compounds > lenalidomide
Page last updated: 2024-09-05

lenalidomide and buparlisib

lenalidomide has been researched along with buparlisib in 2 studies

Compound Research Comparison

Studies
(lenalidomide)		Trials
(lenalidomide)		Recent Studies (post-2010)
(lenalidomide)		Studies
(buparlisib)		Trials
(buparlisib)		Recent Studies (post-2010) (buparlisib)
3,5327252,85025648252

Protein Interaction Comparison

ProteinTaxonomylenalidomide (IC50)buparlisib (IC50)
Chain A, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoformHomo sapiens (human)0.262
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformRattus norvegicus (Norway rat)0.117
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)0.1363
Cytochrome P450 1A2Homo sapiens (human)0.011
Cytochrome P450 3A4Homo sapiens (human)0.027
Cytochrome P450 2C8Homo sapiens (human)0.04
Cytochrome P450 2B6Homo sapiens (human)0.011
Phosphatidylinositol 3-kinase regulatory subunit alphaHomo sapiens (human)0.0878
Cytochrome P450 2C19Homo sapiens (human)0.372
Aldo-keto reductase family 1 member C3Homo sapiens (human)8.7
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)0.055
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)0.2507
Serine/threonine-protein kinase mTORHomo sapiens (human)1.9814
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)0.5654
DNA-dependent protein kinase catalytic subunitHomo sapiens (human)6.917
Phosphatidylinositol 3-kinase catalytic subunit type 3Homo sapiens (human)2.4905
Phosphoinositide 3-kinase regulatory subunit 5Homo sapiens (human)0.129
Serine/threonine-protein kinase mTOR Mus musculus (house mouse)0.832
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformRattus norvegicus (Norway rat)0.523

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Batchelor, TT; Grommes, C; Nayak, L; Tun, HW1

Reviews

1 review(s) available for lenalidomide and buparlisib

ArticleYear
Introduction of novel agents in the treatment of primary CNS lymphoma.
    Neuro-oncology, 2019, 02-19, Volume: 21, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape

2019

Other Studies

1 other study(ies) available for lenalidomide and buparlisib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013